Blood cancers

Time to next treatment endpoint suits complexity of CTCL

An international group of clinicians has proposed time to next treatment (TTNT) as a clinically meaningful endpoint to be applied in future studies of primary cutaneous T-cell lymphoma (CTCL). Writing in the Open Access journal Cancers, the UK, US and Australian authors said TTNT was a useful surrogate for the duration of clinical benefit. It ...

Already a member?

Login to keep reading.

© 2021 the limbic